Farewell and thank you to Head of Research Dr Lisa Melton
After eight years with MS Research Australia it is with gratitude that we say farewell at the end of the month to our Head of Research, Dr Lisa Melton, who is pursuing an exciting new opportunity in the higher education sector.
Dr Melton has been an integral member of the team since 2011 and has contributed significantly to the research strategic plan and organisational achievements. Since she joined, MS Research Australia’s role has progressed from a national to an increasingly global one and Dr Melton has overseen great changes in the outlook for many people living with MS.
Some of Dr Melton’s outstanding achievements include: the development and being secretariat of the world first vitamin D prevention trial (PrevANZ); being pivotal to the smooth running of our Australian MS Longitudinal Study; managing and overseeing many of MS Research Australia’s collaborative platforms and research committees; and leading the internal management of the Research Management Council.
Dr Melton was also a valued member of the Scientific Advisory Committee of the International Progressive MS Alliance and was singled out for her valuable contributions to the Alliance including being asked to head up one of the research streams. Additionally, her exceptional written communications style and mentoring of fellow research colleagues resulted in Dr Melton and MS Research Australia being asked to write the content for the MS International Federation Research Newsletter.
New appointments: Head of Research and Deputy Head of Research
We are excited to announce that effective from June 1 2019, Dr Melton will hand over to our current Deputy Head of Research, Dr Julia Morahan, who will be promoted to the Head of Research position.
Dr Morahan has been with MS Research Australia for seven years and in addition to her responsibilities as Deputy Head of Research, has experience coordinating the MS Research Australia Brain Bank and the national MS Research Australia platform that focuses on genetics (ANZgene).
Dr Morahan has a Bachelor of Medical Science (Hons) from the University of Sydney and a PhD in Neurology and Genetics undertaken at the Royal Prince Alfred Hospital in Sydney. Following her PhD she spent time investigating Motor Neuron Disease (MND) before switching her focus to MS. She became the first recipient of a joint MS Research Australia – MS UK Fellowship which was supported by the Macquarie Group Foundation, to work at the University of Oxford, and joined MS Research Australia upon her return to Sydney in 2012.
Dr Hamish Campbell will take over from Dr Morahan as Deputy Head of Research. Dr Campbell has been with MS Research Australia for three years, with responsibilities including overseeing the communication of research information to the MS Research Australia community, the NSW MS Research Network and the MS Clinical Trials Network.
Dr Campbell holds a Bachelor of Science (Hons) in Genetics and a PhD in Molecular Cell Biology from the University of Otago in New Zealand. Following his PhD he worked at the Children’s Medical Research Institute in Sydney, where his primary research focused on the immune system, autoimmune disease and cancer. Prior to joining MS Research Australia in 2016, Hamish co-authored a number of scientific articles, was an invited speaker at international conferences and has extensive experience in the governance of science with previous positions on ethics, biosafety and scientific grant advisory committees.
Commenting on the changes, MS Research Australia CEO Dr Matthew Miles said “Dr Lisa Melton has been an extremely valuable member of the team and will be greatly missed. I’d like to thank her for everything she has done for MS Research Australia and the MS community at large.”
Richard Bergman, MS Research Australia Chair, added “Dr Julia Morahan and Dr Hamish Campbell are excellently placed to take up their new positions having spent over 10 years between them at MS Research Australia. We are delighted to take this opportunity to promote from within our organisation and we have a fantastic team in place for the imminent growth ahead as we move closer to our goal to stop and reverse MS.”